Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation: 2021-2025

Historic Share-based Compensation for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $13.2 million.

  • Krystal Biotech's Share-based Compensation fell 1.22% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year increase of 18.59%. This contributed to the annual value of $49.1 million for FY2024, which is 23.02% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Share-based Compensation is $13.2 million, which was down 6.84% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Share-based Compensation ranged from a high of $14.1 million in Q2 2025 and a low of $2.3 million during Q1 2021.
  • For the 3-year period, Krystal Biotech's Share-based Compensation averaged around $11.8 million, with its median value being $13.2 million (2025).
  • In the last 5 years, Krystal Biotech's Share-based Compensation surged by 177.99% in 2022 and then fell by 10.90% in 2024.
  • Over the past 5 years, Krystal Biotech's Share-based Compensation (Quarterly) stood at $5.1 million in 2021, then surged by 85.66% to $9.6 million in 2022, then grew by 3.15% to $9.9 million in 2023, then spiked by 35.55% to $13.4 million in 2024, then dropped by 1.22% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q3 2025, $14.1 million for Q2 2025, and $13.5 million during Q1 2025.